National Plan for Epilepsy Act
The National Plan for Epilepsy Act would direct the Secretary of Health and Human Services to create and maintain a national plan to prevent, diagnose, treat, and cure epilepsy. The plan would coordinate federal research and services across agencies, estimate federal investment in epilepsy, encourage development of treatments and care strategies, improve early diagnosis and care coordination, and consider the physical, mental, and social effects of epilepsy on patients and caregivers. It also requires public input, ongoing updates, and coordination with international bodies where possible.
The bill establishes an Advisory Council on Epilepsy Research, Care, and Services made up of federal officials, people living with epilepsy, caregivers, clinicians, researchers, and nonprofit representatives. That council would meet quarterly, hold public meetings, convene broader expert meetings every two years, and submit reports to the Secretary and Congress on federally funded epilepsy efforts, priorities, and recommendations. The Secretary would also submit annual reports to Congress, and federal agencies with relevant epilepsy data would be required to share it for reporting purposes. The program would sunset on December 31, 2035.
The bill would amend Part B of title III of the Public Health Service Act by adding a new Section 320C, creating a federal epilepsy coordination framework within HHS. It would not directly change eligibility for benefits or impose mandates on private parties, but it would require interagency coordination, data sharing among federal agencies, recurring assessments and reports to Congress, and formal consultation with stakeholders. The measure would affect federal public health research, surveillance, care coordination, and policy planning for people with epilepsy, caregivers, providers, researchers, and epilepsy-focused nonprofits.
The available context suggests generally favorable sentiment. The bill was introduced with bipartisan support from Senators Schmitt, Klobuchar, Boozman, and Hassan, which indicates cross-party interest in addressing epilepsy research and care. There are no recorded committee transcripts or votes in the provided material, so there is no evidence of formal opposition in the available record. The bill’s findings emphasize the seriousness of epilepsy, its prevalence, mortality risk, and economic burden, reinforcing a policy rationale that is likely to be broadly sympathetic.
No specific points of contention are documented in the provided materials. Potential areas for debate, based on the bill text, could include the scope of federal coordination, the reporting and data-sharing requirements, the composition and authority of the advisory council, and whether the federal government should create a disease-specific national plan rather than rely on existing research and public health programs. However, the record provided does not show any stated objections from lawmakers, agencies, or stakeholders.